(Q46325862)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

C A Wijbrandts

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

D M Gerlag

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

F Rustenburg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

T C T M van der Pouw Kraan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

B A C Dijkmans

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

P P Tak

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

C L Verweij

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

17 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

622-629

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/gene.2010.34

5 February 2020

exact match

0 references

cites work

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Cytokines in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Predicting the future of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

The Stanford Microarray Database: implementation of new analysis tools and open source release of software

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Significance analysis of microarrays applied to the ionizing radiation response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Cluster analysis and display of genome-wide expression patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

PANTHER: a library of protein families and subfamilies indexed by function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

The response to anti-TNF-α treatment: gene regulation at the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

7 January 2021

Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

7 January 2021

Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

7 January 2021

Uncoupling of inflammation and destruction in rheumatoid arthritis: myth or reality?

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

7 January 2021

Validation of rheumatoid arthritis improvement criteria that include simplified joint counts

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

7 January 2021

Gene expression profiling in rheumatology

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

7 January 2021

A subtype of multiple sclerosis defined by an activated immune defense program

1 reference

https://api.crossref.org/works/10.1038%2FGENE.2010.34

7 January 2021

Identifiers

DOI

10.1038/GENE.2010.34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20555356%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference